1. Home
  2. GANX vs GEOS Comparison

GANX vs GEOS Comparison

Compare GANX & GEOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • GEOS
  • Stock Information
  • Founded
  • GANX 2017
  • GEOS 1980
  • Country
  • GANX United States
  • GEOS United States
  • Employees
  • GANX N/A
  • GEOS N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • GEOS Industrial Machinery/Components
  • Sector
  • GANX Health Care
  • GEOS Industrials
  • Exchange
  • GANX Nasdaq
  • GEOS Nasdaq
  • Market Cap
  • GANX 69.0M
  • GEOS 72.9M
  • IPO Year
  • GANX 2021
  • GEOS 1997
  • Fundamental
  • Price
  • GANX $1.64
  • GEOS $17.21
  • Analyst Decision
  • GANX Strong Buy
  • GEOS
  • Analyst Count
  • GANX 5
  • GEOS 0
  • Target Price
  • GANX $8.20
  • GEOS N/A
  • AVG Volume (30 Days)
  • GANX 614.4K
  • GEOS 191.3K
  • Earning Date
  • GANX 11-13-2025
  • GEOS 08-07-2025
  • Dividend Yield
  • GANX N/A
  • GEOS N/A
  • EPS Growth
  • GANX N/A
  • GEOS N/A
  • EPS
  • GANX N/A
  • GEOS N/A
  • Revenue
  • GANX N/A
  • GEOS $115,527,000.00
  • Revenue This Year
  • GANX N/A
  • GEOS N/A
  • Revenue Next Year
  • GANX N/A
  • GEOS N/A
  • P/E Ratio
  • GANX N/A
  • GEOS N/A
  • Revenue Growth
  • GANX N/A
  • GEOS N/A
  • 52 Week Low
  • GANX $1.36
  • GEOS $5.51
  • 52 Week High
  • GANX $3.19
  • GEOS $21.60
  • Technical
  • Relative Strength Index (RSI)
  • GANX 43.33
  • GEOS 51.03
  • Support Level
  • GANX $1.55
  • GEOS $16.10
  • Resistance Level
  • GANX $1.78
  • GEOS $17.29
  • Average True Range (ATR)
  • GANX 0.13
  • GEOS 1.34
  • MACD
  • GANX -0.03
  • GEOS -0.41
  • Stochastic Oscillator
  • GANX 18.00
  • GEOS 29.45

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About GEOS Geospace Technologies Corporation (Texas)

Geospace Technologies Corp is engaged in designing and manufacturing seismic instruments and non-seismic equipment used in the oil and gas industry. The company has three different segments: oil and gas markets, adjacent markets, and emerging markets. The oil and gas markets segment, which accounts for the majority of the company's revenue, includes traditional exploration products, wireless exploration products, and reservoir characterization products and services. The adjacent markets business is closely tied to the oil and gas markets and includes imaging products and industrial products. The company operates globally across Asia, Canada, Europe, the United States, South America, Mexico, and other regions with a majority of its revenue being generated within the United States.

Share on Social Networks: